UK: UK Early Access To Medicines Scheme - A New Era For Patient Access

Last Updated: 24 July 2014
Article by Karen Taylor

Most Read Contributor in UK, August 2017

In one of our previous blogs we discussed the US Food and Drug Administration's (FDA's) introduction of the 'breakthrough' designation concept as a way of improving earlier access to medicines for patients with high unmet medical need. In this blog we're focussing on the Early Access to Medicines Scheme (EAMS), a similar scheme launched by the UK's Medicines and Healthcare products Regulatory Agency (MHRA) in April 2014. EAMS is a voluntary scheme that provides an accelerated route to market for drugs in the UK and aims to "give patients with life threatening or seriously debilitating conditions access to medicines that do not yet have marketing authorisation".1

Drugs under EAMS will be in phase III or, in exceptional circumstances (if data is compelling and there is a significant unmet need), late stage phase II trials. To gain marketing authorisation (MA) they will still need to go through the full clinical trials and drug licencing process, the MHRA highlight EAMS is not a replacement to the MA process and will only impact 5-10 drugs a year.

Three conditions must be met in sequential order for a drug to be accepted onto EAMS:

  • a drug must first be awarded the status of 'promising innovative medicine' (PIM) by the MHRA, a step that mirrors the FDA's 'breakthrough' status. PIM is reserved for drugs that are "likely to demonstrate significant benefit for patients in life-threatening or seriously debilitating conditions."2
  • the drug manufacturer must then apply for 'EAMS scientific opinion' – the final MHRA evaluation process. The primary aim is to ensure an acceptable risk/ reward trade-off using available clinical trial data. The secondary aim is to develop guidelines and information to allow prescribers and patients to make informed decisions on drug use
  • if accepted the manufacturer must make the drug available to the NHS free of charge for as long as it's included in EAMS. Inclusion is guaranteed for a maximum of a year on the condition that subsequent clinical trial data is shared periodically and does not compromise the risk/ reward trade-off. Once an EAMS drug receives approval through traditional approval channels it is automatically removed from EAMS

There are a number of potential benefits of this scheme which impact a wide range of stakeholders:

  • patients benefit from earlier access to treatments that could significantly improve survival and quality of life. It's thought the scheme will allow patients and doctors access to new medicines two years earlier than is currently the case
  • drug companies benefit from earlier regulatory guidance and collection of real world evidence of impact of the drug (evidence derived from patients outside of the tightly controlled and monitored clinical trial setting) to support licencing and health technology assessment (HTA) opinions. Although the granting of a PIM designation will not be made publically available, the UK Government believes it will be in a company's interest to make this information available because it will signal to investors that a therapy is on the 'right track'
  • the UK economy should benefit as life science companies increase their investment in the UK as it offers the opportunity to work with doctors and patients earlier in the drug's lifecycle, and allows them faster access to patients who will benefit from their new medicine.

For EAMS to realise its potential, the engagement of drug companies is essential. Before deciding to engage, drug companies will need to consider a number of potential risks of EAMS inclusion, such as:

  • Reputational risk -The MHRA has provided reassurance that negative EAMS opinions, which might cast doubt on a drug's effectiveness or safety profile, will not be made public. However, there needs to be more clarity of how the MHRA, as a public body, will respond to freedom of information requests. The impact of a withdrawn EAMS opinion also needs to be considered as do risks associated with releasing early clinical data as part of the approval process.
  • Financial and other risk -The total direct cost of applying for EAMS approval, excluding the cost of preparing the submission, is £33,027 (£4,027 for a PIM application and £29,000 for a 'scientific opinion' of a new molecular entity). A positive EAMS opinion will incur additional costs in relation to providing the drug and any necessary non-standard diagnostic technology, given these are to be provided free of charge to the treatable patient population. There are also costs associated with keeping an EAMS opinion up to date. Financial risks are only likely to deter smaller biotech companies but, as the source of much of today's innovation, these represent an important stakeholder group.

EAMS has so far been received positively by industry and patient groups but with caveats around funding, data clarity and how commissioning of the therapy by the NHS will work. A planned review of EAMS one or two years down the line may help to ensure these and any other concerns are addressed. Until then helping drug companies to better understand EAMS benefit on licencing and HTA opinions could increase interest in the scheme; engaging the National Institute for Health and Care Excellence (NICE) in the EAMS process could be one solution to provide reassurance of favourable HTA opinions. However, companies not considering the whole EAMS process may still apply for PIM status, costing just £4,027, a relatively small price to pay if it attracts potential acquirers or strengthens negotiating power when entering into in-licensing/ co-development agreements.

It is still early days for EAMS and as yet no formal applications have been made. Success will likely depend on the experience of the first few pioneering companies that 'feel' their way through the system and refine its evolution into something that can deliver on the goal of helping patients most in need.




The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.